Add to Calendar 3/21/2019 8:00:00 AM 3/21/2019 10:00:00 AM Overcoming Challenges in Immuno Oncology Clinical Trials Aimed at those who are eager to hear about and discuss some of the latest developments in Cancer Immno oncology (IO), our distinguished panel will focus the forum discussion on dose-finding, biomarker development and endpoints for IO and IO-IO combination clinical trials. For those not familiar with IO we’ll provide a brief including basic principles and a few examples like checkpoint inhibitors. We’ll explore what is different for IO and for IO-IO combinations dose finding compared with traditional chemo dose finding. You’ll learn about new strategies underway for IO biomarker development that can help speed up development such as seamless adaptive designs, introduction of Bayesian paradigm into frequentist designs, and more. Finally, we will wrap up with a look at modern techniques for clinical trial endpoints and statistics including PFS versus OS as primary and RECIST vs irRECIST. Come join this interactive conversation. MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
Senior Director of Biostatistics, TESARO
Dr. Guo earned MS in Biostatistics from University of Massachusetts, Amherst and a PhD in Biostatistics from Boston University. Prior to joining TESARO, she worked at the Harvard School of Public Health, Harvard Clinical Research Institute, Synta Pharmaceuticals, and EMD Serono. She has extensive experience in developing medicines in Immuno-Oncology including dostarlimab (TESARO) , avelumab (EMD Serono) and TGF-β TRAP (EMD Serono) as well as small molecules such as ZEJULA (TESARO) and Ganetespib (Synta).